Comparative Pharmacology
Head-to-head clinical analysis: SULF 15 versus SULFACEL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 15 versus SULFACEL 15.
SULF-15 vs SULFACEL-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
150 mg orally twice daily for 14 days.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)